Prelude Capital Management, LLC Athenex, Inc. Transaction History

Prelude Capital Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 16, 2020	SELL	$10.26 - $14.55 $84,429 - $119,731	-8,229 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$7.11 - $13.76 $6,626 - $12,824	932 Added 12.77%	8,229 $113,000
Q1 2020 May 15, 2020	SELL	$5.71 - $15.85 $155,563 - $431,817	-27,244 Reduced 78.87%	7,297 $56,000
Q4 2019 Feb 14, 2020	BUY	$9.6 - $17.75 $331,593 - $613,102	34,541 New	34,541 $527,000
Q1 2019 May 15, 2019	SELL	$11.11 - $13.49 $8,632 - $10,481	-777 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$10.24 - $15.49 $364,216 - $550,948	-35,568 Reduced 97.86%	777 $10,000
Q3 2018 Nov 14, 2018	BUY	$15.53 - $19.97 $295,504 - $379,989	19,028 Added 109.88%	36,345 $565,000
Q2 2018 Aug 14, 2018	BUY	$15.88 - $19.5 $274,993 - $337,681	17,317 New	17,317 $323,000

1.46M

Ticker ATNX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 156,790,000
Market Cap $1.57M
Description
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral paclitaxel and encequidar,...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.